← Leaderboards
Patrick Pj Phillips
University Of California, San Francisco
$2,006,324
Attributed
$6,018,972
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,018,972 · 3
By mechanism
R33$3,789,374 · 1
R61$2,229,598 · 2
Top collaborators
- Christina Yoon7 shared
- David Wesley Dowdy5 shared
- Annettee Olivia Nakimuli2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Bruce L Miller$34,542,477
- Maria Luisa Gorno Tempini$28,653,126
- Adithya Cattamanchi$24,815,234
- Scarlett L Gomez$14,448,454
- John Alan Shepherd$11,517,792
Others in their field
Other Emerging Leaders on “Recommendation”
- Kimberly Smith · Ppd Development Lp$115,671,664
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$72,192,168
- Dwayne Forquer · Leidos Biomedical Research, Inc.$50,844,487
- Susan M Landau · University Of California Berkeley$47,252,026
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Claudia Valmonte · The Emmes Company, Llc$37,865,589
Research focus
RecommendationUgandaPoliciesRandomized TrialScreeningTuberculosisIncidencePoint Of CarePrimary EndpointRandomizedC-Reactive ProteinRegimenDiagnosisSymptomsBlood CapillariesFutureInnovationMortalityPreventPreventive TherapyPrimary OutcomeClinicAfricaDetection
Grant awards (7)
Optimal tuberculosis screening and tuberculosis preventive therapy delivery strategies to improve maternal and birth outcomes among pregnant women with HIV in Uganda: a randomized trial$853,975
R61 · FY2025 · HL
Optimal tuberculosis screening and tuberculosis preventive therapy delivery strategies to improve maternal and birth outcomes among pregnant women with HIV in Uganda: a randomized trial$411,682
R61 · FY2025 · HL
Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial$711,595
R33 · FY2024 · HL
Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial$1,056,953
R33 · FY2023 · HL
Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial$1,060,388
R33 · FY2022 · HL
Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial$960,438
R33 · FY2021 · HL
Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial$963,941
R61 · FY2019 · HL